vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and CENTURY CASINOS INC (CNTY). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $138.0M, roughly 1.0× CENTURY CASINOS INC). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -13.0%, a 48.5% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 0.2%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-4.7M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 0.7%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Century Casinos, Inc. is a gambling company based in Colorado Springs, Colorado.
ADMA vs CNTY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $138.0M |
| Net Profit | $49.4M | $-17.9M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 7.6% |
| Net Margin | 35.5% | -13.0% |
| Revenue YoY | 18.4% | 0.2% |
| Net Profit YoY | -55.9% | 80.1% |
| EPS (diluted) | $0.20 | $-0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $138.0M | ||
| Q3 25 | $134.2M | $153.7M | ||
| Q2 25 | $122.0M | $150.8M | ||
| Q1 25 | $114.8M | $130.4M | ||
| Q4 24 | $117.5M | $137.8M | ||
| Q3 24 | $119.8M | $155.7M | ||
| Q2 24 | $107.2M | $146.4M | ||
| Q1 24 | $81.9M | $136.0M |
| Q4 25 | $49.4M | $-17.9M | ||
| Q3 25 | $36.4M | $-10.5M | ||
| Q2 25 | $34.2M | $-12.3M | ||
| Q1 25 | $26.9M | $-20.6M | ||
| Q4 24 | $111.9M | $-90.3M | ||
| Q3 24 | $35.9M | $-8.1M | ||
| Q2 24 | $32.1M | $-41.6M | ||
| Q1 24 | $17.8M | $-13.5M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 7.6% | ||
| Q3 25 | 38.0% | 11.1% | ||
| Q2 25 | 35.1% | 11.0% | ||
| Q1 25 | 30.4% | 5.5% | ||
| Q4 24 | 32.6% | -45.5% | ||
| Q3 24 | 33.1% | 11.5% | ||
| Q2 24 | 36.6% | 9.7% | ||
| Q1 24 | 26.7% | 6.1% |
| Q4 25 | 35.5% | -13.0% | ||
| Q3 25 | 27.1% | -6.9% | ||
| Q2 25 | 28.1% | -8.2% | ||
| Q1 25 | 23.4% | -15.8% | ||
| Q4 24 | 95.2% | -65.6% | ||
| Q3 24 | 30.0% | -5.2% | ||
| Q2 24 | 29.9% | -28.4% | ||
| Q1 24 | 21.7% | -10.0% |
| Q4 25 | $0.20 | $-0.62 | ||
| Q3 25 | $0.15 | $-0.35 | ||
| Q2 25 | $0.14 | $-0.40 | ||
| Q1 25 | $0.11 | $-0.67 | ||
| Q4 24 | $0.45 | $-2.95 | ||
| Q3 24 | $0.15 | $-0.26 | ||
| Q2 24 | $0.13 | $-1.36 | ||
| Q1 24 | $0.08 | $-0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $68.9M |
| Total DebtLower is stronger | $72.1M | $328.9M |
| Stockholders' EquityBook value | $477.3M | $-97.7M |
| Total Assets | $624.2M | $1.1B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $68.9M | ||
| Q3 25 | $61.4M | $77.7M | ||
| Q2 25 | $90.3M | $85.5M | ||
| Q1 25 | $71.6M | $84.7M | ||
| Q4 24 | $103.1M | $98.8M | ||
| Q3 24 | $86.7M | $118.8M | ||
| Q2 24 | $88.2M | $123.2M | ||
| Q1 24 | $45.3M | $136.5M |
| Q4 25 | $72.1M | $328.9M | ||
| Q3 25 | $72.4M | $329.3M | ||
| Q2 25 | — | $328.0M | ||
| Q1 25 | — | $328.8M | ||
| Q4 24 | $72.3M | $328.2M | ||
| Q3 24 | — | $327.5M | ||
| Q2 24 | — | $328.8M | ||
| Q1 24 | — | $328.5M |
| Q4 25 | $477.3M | $-97.7M | ||
| Q3 25 | $431.2M | $-78.6M | ||
| Q2 25 | $398.3M | $-66.9M | ||
| Q1 25 | $373.4M | $-54.3M | ||
| Q4 24 | $349.0M | $-34.7M | ||
| Q3 24 | $231.9M | $56.8M | ||
| Q2 24 | $188.3M | $64.6M | ||
| Q1 24 | $153.7M | $106.1M |
| Q4 25 | $624.2M | $1.1B | ||
| Q3 25 | $568.7M | $1.2B | ||
| Q2 25 | $558.4M | $1.2B | ||
| Q1 25 | $510.6M | $1.2B | ||
| Q4 24 | $488.7M | $1.2B | ||
| Q3 24 | $390.6M | $1.3B | ||
| Q2 24 | $376.4M | $1.3B | ||
| Q1 24 | $350.9M | $1.3B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | 5.77× | ||
| Q2 24 | — | 5.09× | ||
| Q1 24 | — | 3.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-114.0K |
| Free Cash FlowOCF − Capex | $34.6M | $-4.7M |
| FCF MarginFCF / Revenue | 24.8% | -3.4% |
| Capex IntensityCapex / Revenue | 0.8% | 3.3% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-15.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-114.0K | ||
| Q3 25 | $13.3M | $144.0K | ||
| Q2 25 | $21.1M | $11.3M | ||
| Q1 25 | $-19.7M | $-4.6M | ||
| Q4 24 | $50.2M | $-2.3M | ||
| Q3 24 | $25.0M | $7.4M | ||
| Q2 24 | $45.6M | $3.0M | ||
| Q1 24 | $-2.2M | $-11.5M |
| Q4 25 | $34.6M | $-4.7M | ||
| Q3 25 | $-1.1M | $-4.7M | ||
| Q2 25 | $18.7M | $5.5M | ||
| Q1 25 | $-24.4M | $-11.3M | ||
| Q4 24 | $47.5M | $-16.9M | ||
| Q3 24 | $24.0M | $-2.8M | ||
| Q2 24 | $43.6M | $-12.9M | ||
| Q1 24 | $-4.6M | $-29.9M |
| Q4 25 | 24.8% | -3.4% | ||
| Q3 25 | -0.8% | -3.1% | ||
| Q2 25 | 15.3% | 3.6% | ||
| Q1 25 | -21.2% | -8.7% | ||
| Q4 24 | 40.4% | -12.3% | ||
| Q3 24 | 20.0% | -1.8% | ||
| Q2 24 | 40.7% | -8.8% | ||
| Q1 24 | -5.6% | -22.0% |
| Q4 25 | 0.8% | 3.3% | ||
| Q3 25 | 10.7% | 3.2% | ||
| Q2 25 | 2.0% | 3.9% | ||
| Q1 25 | 4.1% | 5.1% | ||
| Q4 24 | 2.3% | 10.7% | ||
| Q3 24 | 0.9% | 6.6% | ||
| Q2 24 | 1.9% | 10.9% | ||
| Q1 24 | 2.9% | 13.5% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
CNTY
| Gaming | $103.9M | 75% |
| Food And Beverage | $13.2M | 10% |
| Hotel | $10.5M | 8% |
| Other | $5.2M | 4% |
| Pari Mutuel And Sports Betting And Igaming | $5.2M | 4% |
